Cellectis in supply and license deal with Takara Bio for RetroNectin

22 March 2016
2019_biotech_test_vial_discovery_big

French biotech company Cellectis (Euronext Paris: ALCLS) has entered into a supply and license agreement with Japan’s Takara Bio (TYO: 4974) for recombinant human fibronectin fragment RetroNectin.

Access to Takara’s RetroNectin will secure Cellectis’ manufacturing processes and expand the company’s UCART production capabilities. Under the terms of the agreement, RetroNectin, which is used for cell engineering, may be applied in the production of both R&D- and GMP-grade Cellectis’ UCART product candidates. Financial terms of the accord are not disclosed.

In 2014 Cellectis sold its Swedish subsidiary Cellectis AB to Takara Bio, in order to concentrate its activities in the field of oncology through the development of chimeric antigen receptor T-cell (CAR-T) immunotherapy products generated through its allogeneic CAR-T platform (The Pharma Letter July 30, 2014).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology